Table 1 Selected studies
From: Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
| Primary medication | AA | AAwd | Abiraterone before docetaxel | Abiraterone after docetaxel | Docetaxel | Cabazitaxel |
|---|---|---|---|---|---|---|
| Source | [17] | [18] | [20] | [34] | [26] | [36] |
| Median duration of PSA response (months) | 12 (3–18) | 7.7 (95% CI: 7.1-8.6) | ||||
| Median time to PSA progression (months) | 5.9 (95% CI: 5.3-10.1) | 11.1 | 10.2 | 6.4 (IQR: 2.2-10.1) | ||
| Mean time to PSA progression (months) | ||||||
| Progression free-survival (months) | 16.5 | 5.6 | 2.8 (95% CI: 2.4-3.0) | |||
| Rate of mortality | 50% | 50% at 16.7 months | 42% | 50% at 18.9 months | 62% | |
| at the end of the study | & | at the time of preplanned interim analysis | & | at the time of cut-off | ||
| 90% at 60 months | 82.8% at 3 years | |||||
| Median survival time (months) | 16.7 (95% CI: 14.3 - 21.5) | 14.8 (95% CI: 14.1-15.4) | 18.9 (95% CI: 17–21.2) | 15.1 (95% CI: 14.1-16.3) | ||
| Median length of follow-up (months) | 24 (range: 3–54) | 22.2 | 12.8 | 20.8 | 12.8 (IQR:, 7.8-16.9) | |
| Median cycles of treatment | 8 (range: 1–21) | 9.5* (range: 1–11) | 6* (IQR: 3–10) | |||
| Median cycle of treatment (monthly equivalent) | 7.13 (range: 1–8.3) | 5 (IQR: 2.3-7.5) |
